-
1 Comment
Cardiff Oncology, Inc is currently in a long term downtrend where the price is trading 48.4% below its 200 day moving average.
From a valuation standpoint, the stock is 59.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 549.8.
Cardiff Oncology, Inc's total revenue rose by 28.8% to $119K since the same quarter in the previous year.
Its net income has dropped by 55.5% to $-7M since the same quarter in the previous year.
Finally, its free cash flow fell by 54.9% to $-5M since the same quarter in the previous year.
Based on the above factors, Cardiff Oncology, Inc gets an overall score of 2/5.
None
Here's how to backtest a trading strategy or backtest a portfolio for CRDF using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
